Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 30, 2025

COLO 205

RRID:CVCL_0218
Type: Cell Line

Proper Citation

(RRID:CVCL_0218)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0218

Proper Citation: (RRID:CVCL_0218)

Sex: Male

Defining Citation: PMID:565251, PMID:2041050, PMID:3335022, PMID:3629545, PMID:6277475, PMID:7651727, PMID:9023415, PMID:9294210, PMID:10051639, PMID:10674020, PMID:10700174, PMID:10737795, PMID:11414198, PMID:12068308, PMID:12584437, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:20215515, PMID:20570890, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23272949, PMID:23631600, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24670534, PMID:24755471, PMID:25485619, PMID:25841592, PMID:25877200, PMID:25926053, PMID:25944804, PMID:25984343, PMID:26537799, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28192450, PMID:28196595, PMID:28683746, PMID:28854368, PMID:29718670, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: N-glycan profiling., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: Fluorescence phenotype profiling., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line

Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Name: COLO 205

Synonyms: Colo 205, CoLo 205, COLO-205, Colo-205, COLO.205, Colo205, COLO205, Co 205, Colorado 205

Cross References: BTO:BTO_0000179, CLO:CLO_0002544, CLO:CLO_0050630, EFO:EFO_0003082, MCCL:MCC:0000107, CLDB:cl826, CLDB:cl5096, AddexBio:C0009018/4908, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CCL-222, BCRC:60054, BioGRID_ORCS_Cell_line:846, BioSample:SAMN03470991, BioSample:SAMN10987610, cancercelllines:CVCL_0218, CCRID:1101HUM-PUMC000132, CCRID:3101HUMTCHu102, Cell_Model_Passport:SIDM00826, ChEMBL-Cells:CHEMBL3308348, ChEMBL-Targets:CHEMBL614561, CLS:300380, ColonAtlas:COLO205, Cosmic:685865, Cosmic:720342, Cosmic:738936, Cosmic:875901, Cosmic:876711, Cosmic:887242, Cosmic:889524, Cosmic:897456, Cosmic:902796, Cosmic:905961, Cosmic:948130, Cosmic:948823, Cosmic:974244, Cosmic:995391, Cosmic:1043806, Cosmic:1044256, Cosmic:1045404, Cosmic:1066207, Cosmic:1067224, Cosmic:1092596, Cosmic:1132577, Cosmic:1154651, Cosmic:1175838, Cosmic:1184101, Cosmic:1187303, Cosmic:1223135, Cosmic:1305351, Cosmic:1310944, Cosmic:1312336, Cosmic:1374634, Cosmic:1479612, Cosmic:1609485, Cosmic:1676745, Cosmic:1708401, Cosmic:1945864, Cosmic:1995368, Cosmic:1998438, Cosmic:2036651, Cosmic:2301968, Cosmic:2560250, Cosmic:2651868, Cosmic:2800580, Cosmic-CLP:905961, DepMap:ACH-001039, ECACC:87061208, EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:180-2-342-3-16-3, GDSC:905961, GEO:GSM2089, GEO:GSM50186, GEO:GSM50250, GEO:GSM206459, GEO:GSM274717, GEO:GSM274718, GEO:GSM274728, GEO:GSM741249, GEO:GSM743441, GEO:GSM750794, GEO:GSM799329, GEO:GSM799392, GEO:GSM827422, GEO:GSM846289, GEO:GSM843490, GEO:GSM886940, GEO:GSM888007, GEO:GSM1153400, GEO:GSM1178029, GEO:GSM1178030, GEO:GSM1178031, GEO:GSM1181248, GEO:GSM1181264, GEO:GSM1346867, GEO:GSM1374451, GEO:GSM1374452, GEO:GSM1448172, GEO:GSM1669683, GEO:GSM2124638, GEO:GSM2549994, IARC_TP53:21116, ICLC:HTL00010, KCB:KCB 200719YJ, KCLB:10222, LINCS_LDP:LCL-1173, Lonza:253, MetaboLights:MTBLS227, NCI-DTP:COLO 205, PharmacoDB:COLO205_221_2019, PRIDE:PXD001550, PRIDE:PXD005235, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0218, PubChem_Cell_line:CVCL_0218, RCB:RCB2127, SKY/M-FISH/CGH:2801, TKG:TKG 0457, Wikidata:Q54814074

ID: CVCL_0218

Record Creation Time: 20250131T194758+0000

Record Last Update: 20250131T195341+0000

Ratings and Alerts

No rating or validation information has been found for COLO 205.

No alerts have been found for COLO 205.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 216 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Jothimani G, et al. (2025) Unraveling the mechanism of microRNA-134 in colon cancer progression: Targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation. Experimental cell research, 444(2), 114385.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Xie B, et al. (2024) Strengthening E-cadherin adhesion via antibody-mediated binding stabilization. Structure (London, England : 1993), 32(2), 217.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703.

Bulat F, et al. (2023) Preclinical PET Imaging of Tumor Cell Death following Therapy Using Gallium-68-Labeled C2Am. Cancers, 15(5).

Griffin P, et al. (2023) High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. Cancer cell international, 23(1), 60.

Wei W, et al. (2023) FBXW7? loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal transduction and targeted therapy, 8(1), 187.

Balmanno K, et al. (2023) ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1. The Biochemical journal, 480(9), 587.

Shen L, et al. (2023) CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1. Pathology oncology research : POR, 29, 1611038.

Al-Abdallat K, et al. (2023) Phytochemical Analysis and Anticancer Properties of Drimia maritima Bulb Extracts on Colorectal Cancer Cells. Molecules (Basel, Switzerland), 28(3).

Alfaifi GH, et al. (2023) Indenyl-thiazole and indenyl-formazan derivatives: Synthesis, anticancer screening studies, molecular-docking, and pharmacokinetic/ molin-spiration properties. PloS one, 18(3), e0274459.

Ak?nc?lar SC, et al. (2023) Identification of mechanism of cancer-cell-specific reactivation of hTERT offers therapeutic opportunities for blocking telomerase specifically in human colorectal cancer. Nucleic acids research, 51(1), 1.

Killarney ST, et al. (2023) Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis. Nature communications, 14(1), 1399.

Rahman MM, et al. (2023) Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer. Cancer research communications, 3(6), 952.

Tawara M, et al. (2023) A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers. Current issues in molecular biology, 45(4), 3658.

Ejima R, et al. (2023) Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas. International journal of molecular sciences, 24(4).

Han M?, et al. (2023) Design, Synthesis, and Anticancer Evaluation of Novel Tetracaine Hydrazide-Hydrazones. ACS omega, 8(10), 9198.

Chen J, et al. (2023) In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation. Cancer cell international, 23(1), 21.

Chen JK, et al. (2023) An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types. bioRxiv : the preprint server for biology.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell, 186(16), 3333.